Authors: Gion, M Peloso, L Mione, R Vignati, G Fortunato, A Saracchini, S Biasioli, R Gulisano, M Cappelli, G

Citation: M. Gion et al., Tumor markers in breast cancer monitoring should be scheduled according toinitial stage and follow-up time: A prospective study on 859 patients, CANCER J, 7(3), 2001, pp. 181-190

Authors: Gion, M Mione, R Leon, AE Luftner, D Molina, R Possinger, K Robertson, JF

Citation: M. Gion et al., CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases, EUR J CANC, 37(3), 2001, pp. 355-363

Authors: Gion, M Mione, R Barioli, P Barichello, M Zattoni, F Prayer-Galetti, T Plebani, M Aimo, G Terrone, C Manferrari, F Madeddu, G Caberlotto, L Fandella, A Pianon, C Vianello, L Amoroso, B

Citation: M. Gion et al., Clinical evaluation of percent free prostate-specific antigen using the AxSYM system in the best analytical scenario, EUR UROL, 37(4), 2000, pp. 460-469

Authors: Gion, M Mione, R Leon, AE Dittadi, R

Citation: M. Gion et al., Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer, CLIN CHEM, 45(5), 1999, pp. 630-637

Authors: Gion, M Mione, R Barioli, P Barichello, M Zattoni, F Prayer-Galetti, T Plebani, M Aimo, G Terrone, C Manferrari, F Madeddu, G Caberlotto, L Fandella, A Pianon, C Vianello, L

Citation: M. Gion et al., Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions, CLIN CHEM, 44(12), 1998, pp. 2462-2470